UNSPSC 51111844: Fadrozole

This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C14H13N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H3988M64PU, chemically known as benzonitrile, 4-(5,6,7,8-tetrahydroimidazo(1,5-a)pyridin-5-yl)- but generally known as fadrozole, which bears US NIH Compound Identifier 59693. European Medicines Agency schedules Fadrozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07497MIG.

UNSPSC 51111844 Fadrozole, a Commodity code, encompasses pharmaceutical active pharmaceutical ingredients and finished-dosage products procured through state and local cooperative purchasing agreements. The recent activity under this code reflects state and regional multistate cooperative purchasing alliances sourcing generic and over-the-counter pharmaceutical products for distribution across participating government facilities, including state agencies, local health departments, correctional systems, and other public-sector healthcare operations. Issuing bodies include state procurement offices administering cooperative purchasing vehicles on behalf of multiple member states and municipalities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with an effective date of July 1, 2026. The procurement specifies distribution through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and requires vendors to submit detailed pricing, product information, and certification of compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. Proposals were due March 26, 2026, with evaluation weighted heavily toward price competitiveness (75 percent) and contract pricing stability (10 percent); vendors must maintain commercial general liability insurance of $5,000,000 per occurrence and network security and privacy liability of $2,000,000. MMCAP reserves discretion to award sole, dual, or multiple vendors based on therapeutic considerations and member-specific needs, with contract terms of two years for new responders and optional extensions, and a 3 percent administrative fee applicable to all purchases.